Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Cerilliant
Boehringer Ingelheim
Deloitte
AstraZeneca
Citi
Julphar
Accenture
Moodys
UBS

Generated: January 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,498,440

« Back to Dashboard

Summary for Patent: 7,498,440
Title:Muscarinic acetylcholine receptor antagonists
Abstract: Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.
Inventor(s): Laine; Damane I. (King of Prussia, PA), Palovich; Michael R. (King of Prussia, PA), McCleland; Brent W. (King of Prussia, PA), Neipp; Christopher E. (King of Prussia, PA), Thomas; Sonia M. (King of Prussia, PA)
Assignee: Glaxo Group Limited (Greenford, Middlesex, GB)
Application Number:11/568,330
Patent Claim Types:
see list of patent claims
Compound; Composition; Delivery;

Drugs Protected by US Patent 7,498,440

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Glaxosmithkline ANORO ELLIPTA umeclidinium bromide; vilanterol trifenatate POWDER;INHALATION 203975-001 Dec 18, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Glaxo Grp England INCRUSE ELLIPTA umeclidinium bromide POWDER;INHALATION 205382-001 Apr 30, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Glaxosmithkline TRELEGY ELLIPTA fluticasone furoate; umeclidinium bromide; vilanterol trifenatate POWDER;INHALATION 209482-001 Sep 18, 2017 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,498,440

PCT Information
PCT FiledApril 27, 2005PCT Application Number:PCT/US2005/014386
PCT Publication Date:November 10, 2005PCT Publication Number: WO2005/104745

Non-Orange Book US Patents Family Members for Patent 7,498,440

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,488,827 Muscarinic acetylcholine receptor antagonists ➤ Subscribe
9,144,571 Muscarinic acetylcholine receptor antagonists ➤ Subscribe
8,853,404 Muscarinic acetylcholine receptor antagonists ➤ Subscribe
9,045,469 Muscarinic acetylcholine receptor antagonists ➤ Subscribe
8,183,257 Muscarinic acetylcholine receptor antagonists ➤ Subscribe
8,309,572 Muscarinic acetylcholine receptor antagonists ➤ Subscribe
8,575,347 Muscarinic acetylcholine receptor antagonists ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,498,440

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Merck
Fish and Richardson
Express Scripts
Chinese Patent Office
Harvard Business School
AstraZeneca
Healthtrust
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot